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Somatic genome editing with 
CRISPR/Cas9 generates and 
corrects a metabolic disease
Kelsey E. Jarrett1,2, Ciaran M. Lee3, Yi-Hsien Yeh1, Rachel H. Hsu1, Rajat Gupta1, 
Min Zhang1, Perla J. Rodriguez2,4, Chang Seok Lee1, Baiba K. Gillard4,5, Karl-Dimiter Bissig6, 
Henry J. Pownall4,5, James F. Martin1,7, Gang Bao3 & William R. Lagor1,2
Germline manipulation using CRISPR/Cas9 genome editing has dramatically accelerated the generation 
of new mouse models. Nonetheless, many metabolic disease models still depend upon laborious 
germline targeting, and are further complicated by the need to avoid developmental phenotypes. We 
sought to address these experimental limitations by generating somatic mutations in the adult liver 
using CRISPR/Cas9, as a new strategy to model metabolic disorders. As proof-of-principle, we targeted 
the low-density lipoprotein receptor (Ldlr), which when deleted, leads to severe hypercholesterolemia 
and atherosclerosis. Here we show that hepatic disruption of Ldlr with AAV-CRISPR results in severe 
hypercholesterolemia and atherosclerosis. We further demonstrate that co-disruption of Apob, whose 
germline loss is embryonically lethal, completely prevented disease through compensatory inhibition 
of hepatic LDL production. This new concept of metabolic disease modeling by somatic genome editing 
could be applied to many other systemic as well as liver-restricted disorders which are difficult to study 
by germline manipulation.
Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for 
the treatment of human disease. Genetically engineered mice are the most frequently used model organism to 
study metabolic liver diseases, and have been invaluable in advancing our knowledge of many human disorders. 
However, many metabolic genes also play important roles in development, and their loss may result in embryonic 
lethality. The mouse genome informatics (MGI) database describes that at least 30% of all homozygous mutant 
lines created are embryonic or perinatal lethal1. Specific examples include methylmalonic aciduria (Mmachc)2, 
mevalonic aciduria (Mvk)3, lipoprotein lipase deficiency (Lpl)4, and hypobetalipoproteinemia (Apob)5, which 
underlie devastating human liver diseases. In some cases, hypomorphic alleles have been developed that reca-
pitulate key aspects of a phenotype, such as ornithine transcarbamylase (Otc) deficiency, where the spf mutant 
has 10%, and the Spfash mutant 5%, of normal liver enzymatic activity6. Nevertheless, establishing a hypomorphic 
mouse model is difficult and often does not fully recapitulate the human disease.
Several methods exist to study liver-expressed metabolic genes in adult mice. The cleanest of these are condi-
tional mouse models, where the gene of interest is deleted by a liver-specific CRE recombinase transgene or on 
demand with viral delivery of CRE. Although robust, this technology is time-consuming and not well suited to 
testing multiple candidate genes, either alone or in combination. Loss-of-function studies can also be performed 
through the use of chemically modified antisense oligonucleotides (ASOs)7, locked nucleic acids8, siRNA nano-
particles9, and viral expression of shRNA10. These methods have advantages for achieving acute knockdown of 
target genes, but all have unique caveats, and leave varying degrees of residual expression and activity. Recent 
advances suggest that somatic genome editing could be used for genetic loss-of-function in adult animals.
Clustered Regularly-Interspaced Short Palindromic Repeats/Cas9 (CRISPR/Cas9) is a bacterial immune sys-
tem that has been adapted for genome editing in mammalian cells11,12. Cas9 is a programmable nuclease that 
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generates double-stranded breaks (DSB) in DNA dictated by binding of a ~20 nucleotide recombinant “guide 
RNA” (gRNA) to the target site. DSB’s produced by Cas9 are most often repaired through the cell’s error-prone 
non-homologous end joining (NHEJ) pathway, resulting in small insertions or deletions (indels). The vast major-
ity of indels shift the reading frame13, introducing a premature stop codon or resulting in nonsense mediated 
decay of the mRNA - effectively “knocking out” a gene. We and others have shown that delivery of CRISPR/Cas9 
can effectively knockout liver-expressed genes through methods such as hydrodynamic tail vein injection14 and 
lipid nanoparticles15. Viral vectors offer the advantage of near complete liver transduction, eliminating potential 
redundancy from neighboring hepatocytes. Adenoviral vectors have been used to deliver CRISPR/Cas9 to disrupt 
Pcsk916 in mouse liver. Adeno-Associated Viral (AAV) vectors have also been used for somatic genome editing in 
adult mouse liver17,18, including the identification of a smaller Cas9 ortholog from Staphylococcus aureus (SaCas9) 
that can edit genes with high specificity18. Collectively, these studies suggest that CRISPR/Cas9 genome editing 
is very efficient in murine hepatocytes. Somatic genome editing using CRISPR/Cas9 might be used to establish 
novel metabolic disease models. Hypercholesterolemia and associated atherosclerosis is a major problem in the 
developed world, and would serve as an excellent test case for modeling a common metabolic disease.
The liver secretes triglyceride-rich very low density lipoprotein (VLDL) particles into the circulation to pro-
vide energy to the rest of the body. These particles each contain one Apolipoprotein B (APOB) molecule as their 
core structural component, an essential player in export of excess triglyceride from the liver. VLDL particles are 
broken down by lipases in the circulation, generating smaller, cholesterol-enriched, low density lipoprotein (LDL) 
particles. Excess LDL is normally removed through the action of the low density lipoprotein receptor (LDLR), 
which is highly expressed in the liver, where it is believed to account for approximately 70% of LDL clearance19,20. 
Mutations in the LDLR gene are the basis of Familial Hypercholesterolemia (FH) (MIM 143890), a Mendelian 
lipid disorder characterized by exceptionally high levels of LDL cholesterol (LDL-C), xanthomas, and severe ath-
erosclerotic vascular disease. We previously showed that human FH could be modeled in chimeric mice through 
transplantation with hepatocytes from an FH patient, and the ensuing hypercholesterolemia corrected by additive 
gene therapy with AAV9 vectors21.
Here we generate the first model of metabolic liver disease via somatic genome editing. Mice treated with 
AAV-CRISPR vectors to somatically disrupt the Ldlr gene in the liver develop a severe hypercholesterolemia 
as well as a systemic metabolic phenotype- atherosclerosis. Concomitant disruption of Apob is protective from 
hypercholesterolemia and atherosclerosis, and demonstrates the utility of somatic genome editing to validate 
potential therapeutic targets for metabolic liver disorders.
Results
Somatic disruption of metabolic genes with AAV-CRISPR. Small guide RNAs were designed using 
E-CRISP (http://www.e-crisp.org) targeting either exon 14 of Ldlr or exon 5 of Apob. The gRNAs were cloned into 
our AAV vector that expresses the gRNA from the U6 promoter, upstream of green fluorescent reporter driven by 
the ubiquitous chicken beta (CB) actin promoter. Male Cas9 transgenic mice22 (6–9 weeks old) were injected with 
6 × 1011 genome copies (GC) of AAV8 encoding the different gRNA’s. Mice were randomly assigned one of three 
groups: (i) BbsI (empty cloning site as a “nontargeting” control, 6 × 1011 GC), (ii) Ldlr gRNA + BbsI (3 × 1011 
each), and (iii) Ldlr gRNA + Apob gRNA (3 × 1011 each). The animals were placed on Western diet, a high fat 
cholesterol-rich diet, followed for 20 weeks, and sacrificed to assess atherosclerosis, plasma cholesterol, Ldlr and 
Apo B protein levels, and editing efficiency (Fig. 1A). Mice in groups receiving a gRNA to Ldlr had greater than 
50% decreases in Ldlr mRNA expression (Fig. 1B). Animals receiving the Apob gRNA showed more than 90% 
knockdown of Apob mRNA (Fig. 1B). For both the Ldlr and Apob transcripts, similar results were obtained using 
primers upstream and downstream of the cut site. LDLR protein was readily detectable in livers from the BbsI 
control group, and nearly completely absent from the Ldlr gRNA and Ldlr + Apob gRNA groups (Fig. 1C). The 
Ldlr gRNA group had a dramatic increase in Apo B-100 and Apo B-48 compared to the control animals, while the 
Ldlr + Apob gRNA treated mice had a nearly complete loss of Apo B protein (Fig. 1D).
Efficiency and specificity of somatic genome editing. The efficiency and specificity of editing was 
assessed by deep sequencing of livers following the 20 week study. In addition to the target regions of Ldlr and 
Apob, we used the COSMID algorithm23 to predict potential off-target sites in the mouse genome. On- and 
off-target sites were amplified by PCR to generate barcoded libraries (n = 4 per group) (Supplementary Table 1). 
Deep sequencing revealed a high degree of editing in the Ldlr gene in both groups receiving the Ldlr gRNA with 
a mean indel formation of 54.3 ± 16.6% (Fig. 2A). In the case of Apob, the group receiving a gRNA targeting this 
gene had an impressive rate of indel formation of 74.1 ± 23.4% (Fig. 2A). The most common mutations were 
small insertions and deletions occurring around positions − 3 to − 5 relative to the Protospacer Adjacent Motif 
(PAM) (Fig. 2B). One of the predicted off-target sites for the Ldlr gene (OT 11) had a low frequency of mutations 
which was detectable above background at 5.12 ± 2.02% (Fig. 2C). This particular off-target site is within an 
intron of the Stx8 gene. No detectable off-target editing was detected for any predicted sites for the Apob gRNA 
(Fig. 2D). However, indel formation was observed at several highly similar predicted sites in mice that received 
the BbsI stuffer sequence present in many CRISPR plasmids24, ranging from 1.3–30% depending on location 
(Supplementary Table 2). Perhaps most interestingly, small insertion events containing sequences from the AAV 
inverted terminal repeats (ITRs) were detected at the cut site with the highest editing efficiency (exon 5 of the 
Apob gene), accounting for 10–26% of the total reads (Fig. 3).
Metabolic disease modeling and correction with CRISPR/Cas9. Mice receiving the control virus 
displayed a gradual rise in plasma cholesterol from the Western diet, reaching a maximum of 350 ± 18.7 mg/dL 
after 20 weeks. The Ldlr gRNA group had significantly higher plasma cholesterol which increased to a maximum 
of 728 ± 174 mg/dL. In contrast, mice receiving both the Ldlr and Apob gRNAs exhibited a rapid drop in plasma 
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cholesterol which remained low for the duration of the 20 weeks, with a final concentration of 125 ± 27.3 mg/
dL (Fig. 4A). The majority of the cholesterol in the mice receiving the Ldlr gRNA was carried in the VLDL and 
IDL/LDL fractions. In contrast, concomitant disruption of Apob caused a dramatic reduction in cholesterol in 
the VLDL and IDL/LDL fractions, with a further lowering of HDL (Fig. 4B). Triglyceride levels were markedly 
increased in the VLDL and IDL/LDL fractions from mice in the Ldlr + BbsI group, but not in control animals or 
those with Apob disruption (Fig. 4C). Plasma free fatty acid levels were slightly lower in the Ldlr + Apob group at 
baseline, and remained low during 20 weeks on the Western Diet, in contrast to the slight increase in the control 
and Ldlr gRNA groups (Supplementary Figure 1). Atherosclerotic lesions were readily visible in whole aortae of 
the mice receiving the Ldlr gRNA with a total lesion area of 2.2% ± 2.1% (Fig. 4D,E). The control mice had no 
detectable lesion as expected for C57BL/6 J mice on this diet. Interestingly, disruption of Apob was atheroprotec-
tive in mice that received Ldlr + Apob gRNAs (Fig. 4D,E) despite the near complete absence of LDLR protein in 
the livers of these animals (Fig. 1C).
Body weights were comparable between all groups (Fig. 5A), but mice that received the Ldlr + Apob gRNAs 
had substantially higher liver weights. (Fig. 5B,C). Livers from these animals were buoyant in aqueous formalin 
solution (Supplementary Figure 2), visibly fatty, and trended towards higher total triglyceride content when meas-
ured enzymatically (Fig. 5D,E). To further investigate lipid content, total lipids were extracted by the Bligh-Dyer 
method25 and separated by thin layer chromatography (Fig. 5F). Cholesteryl ester levels were significantly higher 
in the Ldlr + Apob group (Fig. 5G), and triglycerides trended toward an increase (Fig. 5H). There were no signif-
icant differences between groups in free fatty acid or free cholesterol levels (Fig. 5I,J).
Liver morphology was similar between the BbsI control and Ldlr gRNA groups, with evidence of large lipid 
droplets often displacing the nucleus (macrovesicular steatosis) as expected from prolonged Western diet feeding 
(Fig. 6A). Livers from mice receiving the Ldlr + Apob gRNAs had fewer large lipid droplets, enlarged hepatocytes 
with centralized nuclei, and evidence of many small lipid droplets, indicative of microvesicular steatosis26. To 
confirm this, we immunostained liver sections for Perilipin 2 (PLIN2), a structural protein present on the surface 
of lipid droplets (Fig. 6B). Perilipin 2 staining clearly demarcated large lipid droplets in the control and Ldlr gRNA 
groups, while livers from mice treated with Ldlr + Apob gRNAs showed numerous small lipid droplets per cell 
with intense staining. These data were further confirmed by Western blotting, where PLIN2 protein levels were 
dramatically higher with Apob disruption, reflecting the increased total surface area of numerous small lipid 
droplets (Fig. 6C).
To gain insight into the mechanisms underlying the plasma and liver lipid changes, we performed a survey 
of hepatic genes involved in de novo lipogenesis, fatty acid oxidation, cholesterol synthesis, sterol transport, and 
bile acid metabolism (Supplementary Figure 3). We observed decreased expression of several genes important 
for fatty acid oxidation (Supplementary Figure 3B) in mice that received the Ldlr gRNA or Ldlr + Apob relative 
to the control group. While there was suppression of squalene epoxidase (Sqle) in the Ldlr + Apob group, other 
genes in the cholesterol biosynthetic pathway were not significantly altered (Supplementary Figure 3C). No con-
sistent changes were seen in genes involved in lipogenesis, cholesterol transport, or bile acid metabolism. A recent 
report using antisense oligonucleotides showed that short term knockdown of Apob (three weeks) activated the 
endoplasmic reticulum stress (ER stress) markers glucose regulated protein 78 (GRP78/BIP) and phosphorylated 
Figure 1. Somatic disruption of Ldlr and Apob. (A) Experimental design- Male C57BL/6 J mice were 
injected with a total of 6 × 1011 genome copies of AAV, placed on Western Diet, and followed for 20 weeks. (B) 
Expression of mRNA Ldlr and Apob in the liver using primers upstream and downstream of the gRNA site. (C) 
LDLR and beta tubulin Western blot in mouse liver. (D) Apo B protein levels in plasma. Uncropped Western 
blot images are shown in Supplementary Data. For all panels: BbsI control n = 5, Ldlr gRNA + BbsI n = 5, 
Ldlr + Apob gRNA n = 6; data are represented as mean + /− S.D. and *p < 0.05.
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Figure 2. Deep sequencing of on- and off-target editing. (A) Indel frequency at Ldlr and Apob in mouse 
liver. (B) Most common indels observed at each target locus. Insertions are highlighted in red and deletions are 
shown with dashed lines. (C) Indel frequency at Ldlr and the top ranked off-target sites. (D) Indel frequency 
for Apob and the top ranked off-target sites. Data represent n = 4 for each group, and are reported as mean + 
/− S.D. with *p < 0.05; #denotes a repetitive amplicon resulting in sequencing error.
Figure 3. Insertion of AAV-ITR sequences at a CRISPR/Cas9 target site. AAV ITR insertions at the Apob 
target site. Short ITR sequences were detected at the gRNA cut site 3 bases upstream of the PAM (underlined) in 
all mice receiving the Apob gRNA. Representative sequencing reads are shown.
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eukaryotic initiation factor 2 α (p-eIF2α )27. Thus we sought to determine if somatic disruption of Apob would 
also result in ER stress. We saw that both groups receiving the Ldlr gRNA showed ER stress28 as indicated by 
increases in Bip/Grp-78, Grp94, spliced Xbp1 and Chop relative to the control animals. Interestingly, cleaved Atf6 
was increased only in the Ldlr gRNA group, and Atf4 was selectively elevated in the Ldlr + Apob group (Supplem
entary Figures 4 and 5).
Figure 4. Physiological effects of somatic disruption of Ldlr and Apob. (A) Fasted (5 hr) plasma cholesterol 
levels over time following AAV-CRISPR. (B) Lipoprotein cholesterol levels in plasma pooled from all mice in 
each group separated by size exclusion chromatography. (C) Lipoprotein triglyceride levels in plasma pooled 
from all mice in each group separated by size exclusion chromatography. (D) Quantification of atherosclerotic 
lesion areas in the aortae. (E) En face atherosclerotic lesions in the aortic arch stained with Oil Red O. For all 
panels: BbsI control n = 5, Ldlr gRNA + BbsI n = 5, Ldlr + Apob gRNA n = 6; data are represented as mean + 
/− S.D. and *p < 0.05.
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Figure 5. Impact of Ldlr and Apob disruption on liver lipids. (A) Body weight after 20 weeks on Western diet. 
(B) Liver weight. (C) Ratio of liver to body weight. (D) Triglyceride content per gram of liver. (E) Triglyceride 
content per total liver. (F) Representative thin layer chromatography image showing cholesteryl ester (CE), 
triglyceride (TG), free fatty acid (FA), free cholesterol (FC), diacylglyceride (DAG), and phospholipid (PL). 
Quantitation of liver lipids based on densitometry of TLC plates (G–J). For (A–E): BbsI control n = 5, Ldlr 
gRNA + BbsI n = 5, Ldlr + Apob gRNA n = 6; data are represented as mean + /− S.D. and *p < 0.05. For (F): 
BbsI control n = 3, Ldlr gRNA + BbsI n = 3, Ldlr + Apob gRNA n = 4.
www.nature.com/scientificreports/
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Discussion
We demonstrate that AAV-CRISPR can be used to efficiently disrupt a metabolic gene (Ldlr) in mouse liver, pro-
ducing systemic phenotypes- hypercholesterolemia and atherosclerosis. We also show that it is possible to simul-
taneously disrupt a second gene (Apob) while maintaining similar levels of Ldlr editing. Compensatory disruption 
of Apob dramatically lowered plasma cholesterol, protected from atherosclerosis, and exacerbated hepatic fat 
accumulation resulting in a microvesicular steatosis. To our knowledge, this is the first report of somatic genome 
editing for metabolic disease modeling. Our approach is very efficient, producing a pathological phenotype that 
recapitulates a common human disease. We provide important information about the efficiency and specificity of 
genome editing with AAV vectors. Most importantly, our approach allows for combinatorial disruption, and can 
be used for rapid and efficient functional validation of candidate genes.
The reduction in LDLR and Apo B protein levels appeared even greater than the frequency of Indel formation. 
Several factors may contribute to this disagreement. First, non-parenchymal cells make up approximately 15% of 
the liver, and these cells are generally not transduced with AAV8 based vectors. Secondly, our analysis excludes 
insertions or deletions larger than 30 bases, and very large deletions would not have been captured by PCR. 
Finally, the epigenetic status of the chromatin is also known to play an important role in determining Cas9 acces-
sibility29, so it is possible that transcriptionally active alleles are more efficiently edited. For both Ldlr and Apob, 
similar results were obtained for mRNA expression before or after the cut site, suggesting that the majority of 
indels shift the reading frame and promote nonsense mediated decay (NMD) of the mutant transcripts. Ldlr dis-
ruption was not significantly different between the groups receiving Ldlr gRNA and those receiving Ldlr + Apob 
gRNAs – an important consideration for studies requiring disruption of multiple genes in parallel. Indels were 
found at several highly similar predicted BbsI off-target sites in the mouse genome, indicating this common 
stuffer sequence24 encodes a functional gRNA, and therefore should not be considered as a true non-targeting or 
empty gRNA control. No detectable off-target editing events were identified at the predicted sites for the Apob 
gRNA. We did however observe off-target cutting (~5%) with the Ldlr gRNA at a single site in an intron of the 
Stx8 gene, which resides 25 kb away from the nearest splice junction.
We identified integration of short ITR sequences within the target site of the Apob gene ranging from 10–26% 
of the total reads. There does not appear to be homology between the ITR’s and this site. ITR’s are known to 
have recombinogenic properties30 and can promote AAV integration into the host genome in the presence of 
the Rep protein13. Since our recombinant vectors do not contain Rep or Cap, this may reflect the propensity of 
Figure 6. Concomitant disruption of Ldlr and Apob results in microvesicular steatosis. Liver sections 
from mice injected with BbsI control, Ldlr gRNA or Ldlr + Apob gRNA vectors were analyzed at 20 weeks after 
treatment. (A) H & E staining of livers at 400X magnification. (B) Perilipin 2 (red) immunohistochemistry and 
DAPI (blue) staining on paraffin embedded liver sections shown at 600X magnification. (C) Western blotting 
for Perilipin 2.
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these hairpin structures to interact with host DNA repair machinery. Integration of AAV vector sequences is a 
theoretical safety concern, since increased hepatocellular carcinoma incidence has been observed in mice injected 
with recombinant AAV vectors as neonates31–33, although not as adults34. A recent study identified numerous 
integrations of the wild type AAV2 into the human genome in hepatocellular carcinomas, including candidate 
tumor suppressors35. However, analysis of human liver biopsies from patients undergoing gene therapy suggests 
that recombinant AAV integration events are rare, randomly distributed, and may not pose a major risk of cancer 
or genotoxicity36. Our study appears to be the first report of integration of AAV vector sequences at a cut site 
generated by CRISPR/Cas9. Site-specific integration events at DSB should now be considered in the development 
and safety evaluation of AAV-based genome editing vectors for human gene therapy.
Apo B is an essential component of VLDL, IDL, and LDL particles, but studies of its role in liver are chal-
lenging since whole body deletion of Apob is embryonically lethal. Interestingly, the fatty liver phenotype we 
observe differs from other studies of liver Apob silencing. Previous knockdown of Apob with AAV-shRNA and 
AAV-miRNA resulted in greater than 80% reductions in mRNA levels, and the hepatocytes had large lipid drop-
lets in mice on a chow diet37. In the current work, more than 90% knockdown was observed, and these mice 
exhibited a severe fatty liver with microvesicular steatosis on a Western diet. Our data are in contrast to a recent 
report that compared knockdown of Mttp and Apob using antisense oligonucleotides (ASOs), where Apob inhi-
bition lowered plasma cholesterol and VLDL secretion but did not result in steatosis38. However, our model 
employs genetic loss-of-function rather than knockdown of mRNA, and is therefore more analogous to patients 
with hypobetalipoproteinemia (APOB)39 and abetalipoproteinemia (MTTP)40. In both cases, defects in hepatic 
Apo B secretion result in very low levels of ApoB lipoproteins which are often accompanied by hepatic steatosis in 
addition to intestinal lipid and fat soluble vitamin malabsorption. Liver-directed inhibition of ApoB and/or MTP 
are being pursued as treatments for severe cases of familial hypercholesterolemia (FH)41,42. Our studies support 
the rationale for hepatic Apo B inhibition to lower plasma cholesterol, but also demonstrate severe and potentially 
dangerous hepatic fat accumulation.
In summary, we introduce liver-directed somatic genome editing as a way to model metabolic disorders. 
Disruption of Ldlr was severe enough to elicit a systemic phenotype- hypercholesterolemia and atherosclerosis, 
underscoring the importance of the liver in Apo B lipoprotein metabolism. We also achieved a complete protec-
tion from hypercholesterolemia and atherosclerosis through compensatory inhibition of hepatic Apo B secretion. 
Our data shows that highly efficient genome editing is achievable by this approach, but that off-target events may 
still occur, even with optimal gRNA design. In conclusion, somatic genome editing with AAV-CRISPR is a novel 
and versatile approach to model metabolic disease, and its use will provide valuable information on the optimal 
design of genome editing vectors for human gene therapy.
Materials and Methods
Plasmid construction. The AAV-gRNA expression vector 1179_pAAV-U6-BbsI-gRNA-CB-EmGFP was 
generated by cloning a custom U6-gRNA-CB-EmGFP expression cassette into pAAV-TBG-mcs between the 
SnaBI sites adjacent to each I-terminal repeat (ITR). The E-CRISP algorithm43 was used to design gRNA target-
ing Exon 14 of the murine Ldlr and Exon 5 of murine Apob. The gRNA sequences were cloned into the BbsI site of 
plasmid 1179 using the following oligos- Ldlr top 5′ -CACCTGCTGCTGGCCAAGGACATG-3′ , Ldlr bottom 5′ 
-AAACCATGTCCTTGGCCAGCAGCA-3′ , Apob top 5′ -CACCTCAAGCTGGCCATTCCTGAA-3′ , and Apob 
bottom 5′ -AAACTTCAGGAATGGCCAGCTTGA-3′ . The resulting AAV plasmids (1183_pAAV-U6-Ex14-gR-
NAd-CB-EmGFP and 1184_pAAV-U6-ApoB-gRNA2-CB-EmGFP) both contain a 5 bp insertion in the CB pro-
moter which does not affect EmGFP expression. The complete vector sequences are in Supplemental Methods, 
and the plasmids will be made publicly available through Addgene.
AAV production. The Adenoviral helper plasmid pAdDeltaF6 (PL-F-PVADF6) and the AAV8 packaging 
vector pAAV2/8 (PL-T-PV0007) were obtained from the University of Pennsylvania Vector Core. AAV were 
packaged in 293T cells using the triple transfection method44 and purified by two rounds of CsCl density gradient 
centrifugation45,46. The 293T cells were obtained directly from the American Type Tissue Collection (ATCC, 
CRL-3216) and not further authenticated or tested for mycoplasma contamination. AAV were dialyzed in 10,000 
MWCO Slide-A-Lyzer Cassettes (0.5–3.0 mL) against PBS to remove CsCl, and concentrated using an Amicon 
100 kDa MWCO centrifugal filtration device (EMD Millipore Cat# UFC910008) prior to storage at − 80 °C. 
AAV were titered by Q-PCR using primers to EmGFP: forward: GCATCGACTTCAAGGAGGAC, reverse: 
TGCACGCTGCCGTCCTCGATG following DNase digestion as previously described45.
Animals. Cas9 targeted transgenic mice22 were obtained from Jackson Laboratories. These mice have been 
backcrossed to C57BL/6 J, but still exist on a B6/Sv129 mixed background (Gt(ROSA)26Sortm1.1(CAG-Cas9, 
-EGFP)Fezh/J; Stock #024858). A breeding colony was established and housed with a light cycle from 7 am to 
9 pm. Animals were provided free access to food and water and maintained on a standard chow diet before the 
experiment. Male Cas9-Tg mice were injected with a total AAV dose of 6 × 1011 genome copies (GC) (3 × 1011 per 
gRNA) delivered in PBS by intraperitoneal injection at 6.5–9.5 weeks of age. Animals were randomly allocated 
to the three groups within each cage of littermates at time of injection (BbsI control, Ldlr gRNA + BbsI control, 
Ldlr gRNA + Apob gRNA). Immediately following AAV injection, animals were switched to a Western type diet 
containing 21% fat and 0.21% cholesterol (w/w) (Research Diets D12079B). Mice were fasted for 5 hours prior to 
lipid measurements. Blood was obtained through the retro-orbital plexus using heparinized Natelson collecting 
tubes (Fisher, 0266810), and plasma was isolated by centrifugation at 10,000 g for 7 minutes at 4 °C. All experi-
ments were approved by the Baylor College of Medicine Institutional Animal Care and Use Committee (IACUC) 
under protocol number AN-6243, and all procedures were performed in accordance with the relevant guidelines 
and regulations.
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Quantitative Reverse Transcriptase PCR. RNA was isolated from liver samples using the Qiagen RNeasy 
Mini Kit (74106). One microgram RNA was reverse transcribed using BioRad iScript (170–8891). The qPCR was 
completed with 4 μ L per reaction of 1:20 diluted cDNA using primers against regions upstream and downstream 
of the gRNA cut sites for Ldlr and Apob. Specifically, the Ldlr primer sets span exons 10–11 and exons 16–17, and 
the Apob primer sets span exons 2–3, and exons 12–13, respectively. Some primers used in this study have been 
previously reported47–49. All primers are listed in Supplementary Table 1. Data analysis was performed using the 
Δ Δ cT method50 and graphed using GraphPad Prism 6.
Identification of off-target sites. Potential off-target sites in the mouse genome (mm10) were identi-
fied and ranked using the recently developed bioinformatics program COSMID https://crispr.bme.gatech.edu/ 23 
with the following inclusion criteria, three mismatches without insertions or deletions and two base mismatches 
with an insertion or deletion (1 bp bulge). The top ranked sites were selected for further investigation by deep 
sequencing.
Deep sequencing to quantify CRISPR/Cas9 activity at genomic loci. Genomic DNA was amplified 
using locus specific primers (Supplementary Table 1) for 35 cycles with an annealing temperature of 62 °C. A 
second round PCR amplification was performed with an annealing temperature of 65 °C using 2 uL of primary 
PCR product to add the P5 and P7 adapter sequences and a barcode for each mouse51. Barcoded amplicons were 
purified by gel extraction (Qiagen, 28706). Amplicons for all target regions were pooled in an equimolar ratio and 
subjected to 2 × 250 paired-end sequencing on the Illumina MiSeq platform. Paired-end reads were filtered by an 
average Phred quality (Qscore) greater than 20 and merged into longer single reads from each pair with a mini-
mum overlap of 30 nucleotides using Fast Length Adjustment of Short reads. Alignment to reference sequences 
and indel quantification was carried out as previously described52. Reported indel frequencies and error bounds 
are mean and S.D. derived from data from 4 animals for each treatment.
Western Blotting. Livers were homogenized in radioimmunoprecipitation buffer containing 50 mM Tris pH 
8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium dodecyl sulfate, 0.5% sodium deoxycholate, 150 mM NaCl, and 
protease inhibitors (Roche, 11836153001) using a Polytron tissue homogenizer (PT2100). Protein concentration 
was determined using the bicinchinoic acid protein assay (Pierce, 23227). Proteins (50 μ g liver lysate or 1 μ L 
plasma) were resolved via SDS-PAGE on 4–12% gradient gels (Life Technologies, NP0322BOX), and then trans-
ferred to polyvinylidene fluoride membranes (Millipore, IPFL00010). Membranes were blocked with a 2:1 solu-
tion of Odyssey Blocking Buffer (Li-Cor, 927–40000) and PBS plus 0.05% tween-20 (PBS-T) for 1 hour. Western 
blotting was performed to detect LDLR using a rabbit polyclonal antibody to the C-terminus at a 1:5,000 dilu-
tion53 and a mouse monoclonal antibody to beta tubulin at 1:1000 dilution (University of Iowa- Developmental 
Studies Hybridoma Bank, E7). ApoB was detected using a rabbit polyclonal antibody (Meridian Life Sciences, 
K23300R)54. Detection was performed using goat anti-rabbit 680 nm and goat anti-mouse 800 nm secondary 
antibodies (Rockland, 611-144-002-0.5 and 610-145-002-0.5) with the Odyssey Classic imager (Li-Cor). Western 
blotting for other proteins was performed in an identical manner, and all antibodies and dilutions are provided 
in Supplementary Table 3.
Lipid measurements. Fasted plasma (5 hr) was collected prior to AAV injection, and then at 4, 8, 12, 16 and 
20 weeks thereafter. Total cholesterol was measured using the Wako Cholesterol E Reagent (Wako Diagnostics, 
439–17501) according to the manufacturer’s instructions. Plasma free fatty acid levels were measured using the 
Free Fatty Acid Quantitation Kit (Sigma, MAK044–1KT). Gel filtration chromatography was performed on 190 μ 
l of pooled plasma, diluted to 220 μ L in TBS (10 mM Tris pH 7.5, 100 mM NaCl, 1 mM EDTA, and 1 mM sodium 
azide), and loaded onto a 200 μ L loop on an Amersham-Pharmacia ÄKTA chromatography system equipped with 
two Superose HR6 columns in tandem and eluted with TBS at a flow rate of 0.5 mL/min as previously described55. 
Fractions of 1 mL each were collected, and 100 μ L of each fraction was assayed for total cholesterol and triglyc-
eride, reported in μ g/mL using the Wako Cholesterol E and Thermo Scientific Infinity Triglycerides (TR22421) 
kits. Livers were homogenized in 3 volumes PBS, diluted and then solubilized 1% deoxycholate, and analyzed 
with Infinity TG Reagent (Thermo, TR22321) to determine hepatic triglyceride content as previously described56. 
To assess total lipid levels, lipids were extracted from mouse liver using the Bligh-Dyer method25, and separated 
by thin layer chromatography on 20 × 20 cm plates via hexane: diethyl ether: acetic acid (170:30:1). Lipids were 
resolved with iodine vapor for quantitation and primuline staining for visualization. Staining intensity was quan-
tified using Image Studio Lite (Licor) and normalized to the BbsI control group.
Atherosclerosis studies. Following 20 weeks of Western diet, mice were sacrificed and aortae were dis-
sected from the aortic root to the ileal bifurcation, and then split longitudinally for en face staining with Oil Red 
O (VWR, AAA12989-14)57. Stained aortae were pinned on black paraffin wax using insect pins (Finescience.
com, 26002–20) under PBS, and imaged on a Leica M80 dissection microscope, equipped with a Leica IC80 HD 
camera. Lesion area was manually quantified using the ImageJ58 software and expressed as a percentage of total 
vessel area.
Histology and immunohistochemistry. Tissues were fixed overnight in 10% formalin and dehydrated 
in ethanol. Paraffin embedding, sectioning, and hematoxylin and eosin staining were completed by the Texas 
Digestive Diseases Morphology Core. Slides were imaged at 400× magnification on a Nikon Ci-L brightfield 
microscope. For immunohistochemistry, five micron sections were deparaffinized and rehydrated using standard 
methods. Antigen retrieval was completed in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween-20 in 
PBS, pH 6) in boiling water for 20 minutes followed by three 5-minute PBS rinses. Slides were blocked for an 
hour in blocking solution (5% goat serum, 3% BSA, 0.3% Triton X100, in phosphate buffered saline) and then 
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incubated with PLIN2 primary antibody at 1:200 overnight. Secondary antibody (Molecular Probes, R3717) was 
incubated for 2 hours at room temperature and rinsed five times in PBS for 10 minutes. Coverslips were mounted 
using Dapi Fluormount G (Southern Biotech, 0100–20) and imaged at 600× magnification.
Statistics. The sample size was determined based upon previous experience with Ldlr KO animals, as well as 
a small pilot study involving animals injected with either saline (n = 3) or the Ldlr gRNA (n = 4) fed a Western 
diet for 16 weeks. We calculated that n = 5 animals per group would provide 80% power to detect differences of 
30% in plasma cholesterol with statistical significance set at p < 0.05. The group sizes in the final experiment were 
as follows: BbsI control (n = 5), Ldlr gRNA + BbsI control (n = 6), Ldlr gRNA + Apob gRNA (n = 6). Animals 
were randomly allocated to experimental groups within each cage of littermates, and maintained in the same 
cage throughout the study. Investigators were not blinded during the experiment or when assessing the outcome. 
Pre-determined exclusion criteria included malocclusion or failed injection based on the absence of detectable 
AAV genomes. AAV vector genomes were analyzed in all livers by PCR, and one animal in the Ldlr gRNA group 
was excluded for failed injection (final n = 5). Data were normally distributed and comparisons were performed 
using One Way ANOVA followed by Tukey’s posttest where differences exist. All data are biological and not 
technical replicates, and are presented as the mean or individual data points. In all cases error bars represent the 
standard deviation within the group, and statistical significance was assigned at p < 0.05 (noted with an asterisk*).
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